SciVac Therapeutics Inc.: News Release

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/02/16 -- SciVac Therapeutics Inc. ("SciVac" or the "Company") (TSX: VAC)(OTCQX: SVACD) today announced, in connection with the previously disclosed proposed business combination between SciVac and VBI Vaccines Inc., an updated biography for SciVac's Chief Financial Officer, James J. Martin.

Mr. Martin's biography is set forth below in its entirety:

James J. Martin, C.P.A. has served as SciVac's Chief Financial Officer since August 2014. Mr. Martin previously served as Chief Financial Officer of SafeStitch Medical, Inc., a medical device company, from January 2011 until October 2013, which was shortly after SafeStitch's acquisition by TransEnterix, Inc. Since January 2011, Mr. Martin has also served as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTCBB: NIMU), a company engaged in the development, manufacture and marketing of non-invasive, whole body periodic acceleration therapeutic platforms. Beginning in April 2014, Mr. Martin also served as Chief Financial Officer of Vaporin, Inc. (OTCBB: VAPO), a company engaged in vaporizers and accessories. In March 2015, Vaporin merged with Vapor Corp (NASDAQ: VPCO) and Mr. Martin served as Chief Financial Officer of Vapor Corp. until September 2015. From January 2011 through December 2011, Mr. Martin served as Vice President of Finance of Aero Pharmaceuticals, Inc., referred to as Aero, a privately-held pharmaceutical distributor. From July 2010 until January 2011, Mr. Martin served as the Controller of SafeStitch, NIMS and Aero. From 2008-2010, Mr. Martin served as the Controller of AAR Aircraft Services, Inc., an aerospace and defense company, and from 2005-2008, Mr. Martin served as the Controller of Avborne Heavy Maintenance, Inc., an aviation maintenance repair and overhaul company. In addition to his career in finance and accounting, Mr. Martin served five years in the United States Navy as an Operations Specialist.

About SciVac Therapeutics Inc.

SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company's flagship product, Sci-B-Vac", is a recombinant 3rd generation hepatitis B vaccine. The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.

Important Information for Investors and Stockholders

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to the proposed business combination (the "Proposed Merger") between SciVac and VBI Vaccines Inc. ("VBI"). In connection with the Proposed Merger, VBI and SciVac have and will continue to file relevant materials with the Securities and Exchange Commission (the "SEC") and applicable Canadian securities regulatory authorities ("Canadian Securities Commissions"), including the registration statement on Form F-4 filed by SciVac with the SEC on December 23, 2015, as amended and declared effective by the SEC on April 8, 2016 (the "SciVac F-4"), which includes a combined proxy statement/prospectus (the "VBI Proxy"). INVESTORS AND SECURITY HOLDERS OF VBI AND SCIVAC ARE URGED TO READ THE SCIVAC F-4 AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC AND THE CANADIAN SECURITIES COMMISSIONS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of the SciVac F-4, the VBI Proxy and other documents (if and when available) filed with the SEC by VBI or SciVac through the website maintained by the SEC at www.sec.gov and, in the case of documents of SciVac filed with the Canadian Securities Commissions, on SciVac's SEDAR profile on www.sedar.com. Copies of the documents filed with the SEC by VBI will be available free of charge on VBI's website at http://www.vbivaccines.com or by contacting VBI's Investor Relations Department by email at [email protected] or by phone at (617) 830-3031 x128. Copies of the documents filed with the SEC and the Canadian Securities Commissions by SciVac will be available free of charge on SciVac's website at www.scivactherapeutics.com or by contacting SciVac's Investor Relations Department by email at [email protected] or by phone at (305) 575-4207.

Participants in the Solicitation

VBI, SciVac, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the Proposed Merger. Information about the directors and executive officers of VBI is set forth in the SciVac F-4 and VBI Proxy. Information about the directors and executive officers of SciVac is set forth in the SciVac F-4.

These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the SciVac F-4 and VBI Proxy and may be set forth in other relevant materials to be filed with the SEC and with the Canadian Securities Commissions when they become available.

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties, including statements regarding the ability of SciVac and VBI to consummate the transactions contemplated by the Proposed Merger, whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, general economic conditions and other factors detailed from time to time in the Company's periodic disclosure. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the Company's current expectations and it undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX), the Frankfurt Stock Exchange nor the OTCQX accepts responsibility for the adequacy or accuracy of this news release.

Contacts:
SciVac Therapeutics Inc.
Jim Martin
Chief Financial Officer
305-575-4207
[email protected]
www.scivactherapeutics.com

Source: SciVac Therapeutics Inc.

You May Also Be Interested In

• Trump Media & Technology (DJT) Declines 17% on Concerns Stockholders May Sell Shares
• Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh
• Trump Media & Technology Group (DJT) stock falls as it files to sell shares